Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising genome sequencing, has signed an $88 million Series D financing, bringing the total funds raised to date to $146m.
Temasek, a Singaporean holding company owned by the Government of Singapore, led the round. There was participation from new investors including Third Point and existing backers such as GV, New Science Ventures, Ahren Innovation Capital and Sequoia.
Proceeds will be used to commercialise the company’s proprietary genetic and epigenetic sequencing technology, which easily integrates into existing sequencing platforms to enable more information to be read from DNA.
The technology has been validated by leading genomic research institutions, many of whom have continued using it through early access programmes.
Professor Sir Shankar Balasubramanian, founder of Cambridge Epigenetix, said: “We are pleased to have raised a significant Series D round from high-profile investors to support the commercial launch of the first product from our new multi-omic platform, and the expansion of our organisation.
“Importantly, our sequencing technology works with all sequencers and enhances their accuracy as opposed to replacing or competing with them.
“Further, our technology has the potential to dramatically reduce the cost of genome sequencing, as the low sample requirement and streamlined workflow facilitate its cost-effectiveness and ease of use without sacrificing accuracy. We look forward to product and to making game-changing contributions to DNA sequencing, epigenomic research and precision medicine.”
